ArticleJCEM case reports2026
Ectopic ACTH syndrome in an adult with metastatic Ewing sarcoma.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) accounts for 8-18% of Cushing syndrome cases and is typically due to neuroendocrine tumors such as small cell lung carcinoma and bronchopulmonary neuroendocrine tumors. EAS arising from Ewing sarcoma (EwS) is rare, with only 9 pediatric and 5 adult cases reported to date. We present the case of a 40-year-old woman with refractory, metastatic EwS who developed progressive swelling, fatigue, hypokalemia, profound proximal muscle weakness, and intermittent confusion over 2 months. Physical examination revealed facial plethora, supraclavicular fat pads, hirsutism, ecchymoses, and bilateral lower extremity weakness. Laboratory evaluation was consistent with severe ACTH-dependent hypercortisolism, confirmed to be secondary to EAS after further evaluation, including the radiographic finding of rapid-onset bilateral adrenal hyperplasia. She started metyrapone, an 11-β hydroxylase inhibitor, which resulted in rapid biochemical improvement and allowed for discontinuation of insulin and potassium therapies. Due to the refractory, progressive EwS and the patient's poor performance status, she transitioned to palliative care at home, continuing metyrapone for hypercortisolism management until her death 4 months later. Herein, we summarize the existing literature of EAS in EwS, emphasize the importance of prompt recognition of the condition, and highlight the therapeutic challenges of managing paraneoplastic EAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.